研報掘金丨東吳證券:維持奧比中光“買入”評級,機器人突破有望帶動業績上漲
東吳證券研報指出,奧比中光(688322.SH)爲全球3D視覺感知龍頭,機器人突破有望帶動業績上漲。分產品看,公司主營業務收入主要來自於銷售3D視覺傳感器。23年佔比總營收61.6%,公司已實施多期員工激勵計劃、確認大額股份支付費用,近五年研發費用率持續高於50%,導致淨利潤尚未轉正。當前公司在機器人領域中,產品持續放量,將有望拉動公司營收實現高速增長,帶動公司逐步扭虧。受益於機器人行業訂單持續增長,奧比中光24-26年營收將實現快速增長、利潤有望25年扭虧爲盈,考慮到公司是全球3D視覺感知龍頭,維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.